Sarepta Therapeutics (SRPT) Falls as Anthem says Exondys 51 Not Medically Necessary
Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.
Sarepta Therapeutics (NASDAQ: SRPT) ticks lower after Anthem says Exondys 51 not medically necessary. Shares are down 3.2%.
Anthem's position statement:
"The use of eteplirsen is considered investigational and not medically necessary for all indications, including but not limited to the treatment of Duchenne muscular dystrophy."
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Sarepta's (SRPT) Exondys 51 covered by Humana (HUM) with prior authorization - Bloomberg
- Buffalo Wild Wings (BWLD) November 135 straddle priced for movement of 10.4%
- Sarepta Therapeutics (SRPT) Target of Cautious Article
Create E-mail Alert Related CategoriesFDA, Momentum Movers, Trader Talk
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!